Lymphatic filariasis in children: clinical features, infection burdens and future prospects for elimination.
Identifieur interne : 004D65 ( Main/Exploration ); précédent : 004D64; suivant : 004D66Lymphatic filariasis in children: clinical features, infection burdens and future prospects for elimination.
Auteurs : Ranganatha Krishna Shenoy [Inde] ; Moses J. BockarieSource :
- Parasitology [ 1469-8161 ] ; 2011.
Descripteurs français
- KwdFr :
- Albendazole (administration et posologie), Animaux, Antihelminthiques (administration et posologie), Brugia (), Enfant, Femelle, Filariose lymphatique (), Filariose lymphatique (anatomopathologie), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Humains, Ivermectine (administration et posologie), Mâle, Sol (parasitologie), Wuchereria bancrofti ().
- MESH :
- administration et posologie : Albendazole, Antihelminthiques, Ivermectine.
- anatomopathologie : Filariose lymphatique.
- parasitologie : Sol.
- traitement médicamenteux : Filariose lymphatique.
- épidémiologie : Filariose lymphatique.
- Animaux, Brugia, Enfant, Femelle, Filariose lymphatique, Humains, Mâle, Wuchereria bancrofti.
English descriptors
- KwdEn :
- Albendazole (administration & dosage), Animals, Anthelmintics (administration & dosage), Brugia (drug effects), Child, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (pathology), Elephantiasis, Filarial (prevention & control), Female, Humans, Ivermectin (administration & dosage), Male, Soil (parasitology), Wuchereria bancrofti (drug effects).
- MESH :
- chemical , administration & dosage : Albendazole, Anthelmintics, Ivermectin.
- drug effects : Brugia, Wuchereria bancrofti.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- chemical , parasitology : Soil.
- pathology : Elephantiasis, Filarial.
- prevention & control : Elephantiasis, Filarial.
- Animals, Child, Female, Humans, Male.
Abstract
Lymphatic filariasis (LF), a common parasitic infection in tropical countries, causes lymphoedema of limbs, hydrocele and acute attacks of dermato-lymphangio-adenitis. Recent advances in diagnosis have helped to recognize that LF infection is often acquired in childhood. Newly available diagnostic techniques like sensitive antigen and antibody assays, Doppler ultrasonography and lymphoscintigraphy have helped to understand the subclinical pathology caused by this infection, which was hitherto generally believed to be irreversible. Recent studies indicate that drugs used in the mass drug administration (MDA) programme under GPELF are capable of reversing the sub-clinical lymphatic damage in children and provide benefits other than interruption of transmission. Albendazole and ivermectin used in MDA are effective against soil-transmitted helminthic infections common in children in LF endemic areas. Thus MDA had other 'beyond LF' benefits in treated children including increased appetite, weight gain, greater learning ability and concentration, better school attendance and prevention of anaemia. MDA should no longer be viewed as a measure for interrupting transmission alone. Recent findings of reversibility of early lymphatic pathology in treated children indicate that both MDA and 'foot-hygiene' measures are effective strategies in preventing and managing morbidity. Programme managers should effectively utilize this information to strengthen their advocacy efforts to achieve high and sustainable coverage in MDA.
DOI: 10.1017/S003118201100117X
PubMed: 21810306
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002501
- to stream PubMed, to step Curation: 002501
- to stream PubMed, to step Checkpoint: 002501
- to stream Ncbi, to step Merge: 004575
- to stream Ncbi, to step Curation: 004575
- to stream Ncbi, to step Checkpoint: 004575
- to stream Main, to step Merge: 004E01
- to stream Main, to step Curation: 004D65
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lymphatic filariasis in children: clinical features, infection burdens and future prospects for elimination.</title><author><name sortKey="Shenoy, Ranganatha Krishna" sort="Shenoy, Ranganatha Krishna" uniqKey="Shenoy R" first="Ranganatha Krishna" last="Shenoy">Ranganatha Krishna Shenoy</name><affiliation wicri:level="1"><nlm:affiliation>Filariasis Chemotherapy Unit, TD Medical College Hospital, Alappuzha 688 011, Kerala, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Filariasis Chemotherapy Unit, TD Medical College Hospital, Alappuzha 688 011, Kerala</wicri:regionArea><wicri:noRegion>Kerala</wicri:noRegion></affiliation></author><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21810306</idno><idno type="pmid">21810306</idno><idno type="doi">10.1017/S003118201100117X</idno><idno type="wicri:Area/PubMed/Corpus">002501</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002501</idno><idno type="wicri:Area/PubMed/Curation">002501</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002501</idno><idno type="wicri:Area/PubMed/Checkpoint">002501</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002501</idno><idno type="wicri:Area/Ncbi/Merge">004575</idno><idno type="wicri:Area/Ncbi/Curation">004575</idno><idno type="wicri:Area/Ncbi/Checkpoint">004575</idno><idno type="wicri:Area/Main/Merge">004E01</idno><idno type="wicri:Area/Main/Curation">004D65</idno><idno type="wicri:Area/Main/Exploration">004D65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lymphatic filariasis in children: clinical features, infection burdens and future prospects for elimination.</title><author><name sortKey="Shenoy, Ranganatha Krishna" sort="Shenoy, Ranganatha Krishna" uniqKey="Shenoy R" first="Ranganatha Krishna" last="Shenoy">Ranganatha Krishna Shenoy</name><affiliation wicri:level="1"><nlm:affiliation>Filariasis Chemotherapy Unit, TD Medical College Hospital, Alappuzha 688 011, Kerala, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Filariasis Chemotherapy Unit, TD Medical College Hospital, Alappuzha 688 011, Kerala</wicri:regionArea><wicri:noRegion>Kerala</wicri:noRegion></affiliation></author><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name></author></analytic><series><title level="j">Parasitology</title><idno type="eISSN">1469-8161</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (administration & dosage)</term><term>Animals</term><term>Anthelmintics (administration & dosage)</term><term>Brugia (drug effects)</term><term>Child</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (pathology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Female</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Male</term><term>Soil (parasitology)</term><term>Wuchereria bancrofti (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (administration et posologie)</term><term>Animaux</term><term>Antihelminthiques (administration et posologie)</term><term>Brugia ()</term><term>Enfant</term><term>Femelle</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (anatomopathologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Mâle</term><term>Sol (parasitologie)</term><term>Wuchereria bancrofti ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brugia</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Sol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="parasitology" xml:lang="en"><term>Soil</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Child</term><term>Female</term><term>Humans</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Brugia</term><term>Enfant</term><term>Femelle</term><term>Filariose lymphatique</term><term>Humains</term><term>Mâle</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphatic filariasis (LF), a common parasitic infection in tropical countries, causes lymphoedema of limbs, hydrocele and acute attacks of dermato-lymphangio-adenitis. Recent advances in diagnosis have helped to recognize that LF infection is often acquired in childhood. Newly available diagnostic techniques like sensitive antigen and antibody assays, Doppler ultrasonography and lymphoscintigraphy have helped to understand the subclinical pathology caused by this infection, which was hitherto generally believed to be irreversible. Recent studies indicate that drugs used in the mass drug administration (MDA) programme under GPELF are capable of reversing the sub-clinical lymphatic damage in children and provide benefits other than interruption of transmission. Albendazole and ivermectin used in MDA are effective against soil-transmitted helminthic infections common in children in LF endemic areas. Thus MDA had other 'beyond LF' benefits in treated children including increased appetite, weight gain, greater learning ability and concentration, better school attendance and prevention of anaemia. MDA should no longer be viewed as a measure for interrupting transmission alone. Recent findings of reversibility of early lymphatic pathology in treated children indicate that both MDA and 'foot-hygiene' measures are effective strategies in preventing and managing morbidity. Programme managers should effectively utilize this information to strengthen their advocacy efforts to achieve high and sustainable coverage in MDA.</div></front></TEI><affiliations><list><country><li>Inde</li></country></list><tree><noCountry><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name></noCountry><country name="Inde"><noRegion><name sortKey="Shenoy, Ranganatha Krishna" sort="Shenoy, Ranganatha Krishna" uniqKey="Shenoy R" first="Ranganatha Krishna" last="Shenoy">Ranganatha Krishna Shenoy</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004D65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21810306
|texte= Lymphatic filariasis in children: clinical features, infection burdens and future prospects for elimination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21810306" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |